New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control
Ongoing
This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC